By Fineline Cube 
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong Kong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high‑need therapeutic areas.
Company Snapshot
| Item | Detail |
|---|---|
| Ticker | 688166.SH (China) / HKEX filing |
| Founded | 2001 |
| Core Competencies | Active Pharmaceutical Ingredients (APIs), high‑end finished dosage forms (FDFs), and innovative drug development |
| Commercial Portfolio | 40+ products (12 FDFs, 29 APIs/intermediates) |
| Key Revenue‑Drivers | Micafungin Sodium, Oseltamivir Phosphate, Caspofungin Acetate, Anidulafungin, Fidaxomicin, Eribulin Mesylate, Pimecrolimus |
| Innovative Pipeline | 7 candidates, featuring BGM0504 (GLP‑1/GIP dual‑agonist for Type 2 Diabetes & obesity) |
Why HKEX?
- Capital Efficiency – HKEX offers a large, liquid market with a strong appetite for biotech listings.
- Strategic Visibility – Listing in Hong Kong enhances BrightGene’s profile among global investors and partners.
- Regulatory Synergy – The prospectus aligns with HKEX’s stringent disclosure standards, reinforcing investor confidence.
Pipeline Highlights
- BGM0504 – A GLP‑1/GIP dual‑agonist that has entered Phase II, poised to become a Best‑in‑Class therapy for Type 2 Diabetes and obesity.
- Other Candidates – Six additional molecules across oncology, infectious disease, and metabolic disorders, all supported by robust pre‑clinical data.
Financial Outlook
- Revenue Growth – Over the last fiscal year, BrightGene’s product sales surged 18 %, driven by the expanding market for its antifungal and antiviral APIs.
- Capital Allocation – Proceeds from the HKEX listing will fund clinical development, manufacturing scale‑up, and strategic acquisitions.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech